dan 2163 has been researched along with Depression in 20 studies
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
Excerpt | Relevance | Reference |
---|---|---|
" In a multicentre, 6 months, placebo-controlled trial, amisulpride (50 mg/daily) was compared to imipramine (100 mg/daily) in the treatment of patients with DSM-III-R criteria for primary dysthymia, dysthymia with major depression or major depression in partial remission." | 9.08 | Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. ( Boyer, P; Lecrubier, Y; Rein, W; Turjanski, S, 1997) |
"The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 7.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
" In a multicentre, 6 months, placebo-controlled trial, amisulpride (50 mg/daily) was compared to imipramine (100 mg/daily) in the treatment of patients with DSM-III-R criteria for primary dysthymia, dysthymia with major depression or major depression in partial remission." | 5.08 | Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. ( Boyer, P; Lecrubier, Y; Rein, W; Turjanski, S, 1997) |
"Aminosulpiride is a benzamide used to treat acute or chronic schizophrenia Some researchers believe that early improvement of depression symptoms in patients has a certain predictive effect on the recovery of symptoms after drug treatment for schizophrenia." | 3.96 | Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. ( Ni, Y; Pan, A; Wang, G; Zheng, L; Zhou, B, 2020) |
"The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 3.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
" SEP-4199 had low rates of individual adverse events (<8%) and minimal effects on weight and lipids; median increases in prolactin were +83." | 3.11 | A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. ( Deng, L; Fava, M; Hopkins, SC; Kent, J; Koblan, KS; Loebel, A; Tsai, J, 2022) |
"Psychotic depression is classified as a clinical subtype of major depressive disorder." | 2.73 | Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. ( Papadimitriou, GN; Politis, AM; Psarros, C; Soldatos, CR; Theleritis, CG, 2008) |
"The pharmacological treatment of fibromyalgia is limited to a few drugs that have been demonstrated to be moderately effective in some but not all dimensions of the disease." | 2.50 | Current status of atypical antipsychotics for the treatment of fibromyalgia. ( Calandre, EP; Rico-Villademoros, F; Slim, M, 2014) |
"One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat, 4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment." | 1.34 | Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies. ( Berra, C; Binaschi, L; Borio, R; Torta, R, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (20.00) | 18.2507 |
2000's | 8 (40.00) | 29.6817 |
2010's | 3 (15.00) | 24.3611 |
2020's | 5 (25.00) | 2.80 |
Authors | Studies |
---|---|
Loebel, A | 1 |
Koblan, KS | 1 |
Tsai, J | 1 |
Deng, L | 1 |
Fava, M | 1 |
Kent, J | 1 |
Hopkins, SC | 1 |
Yuan, B | 1 |
Yuan, M | 1 |
Liu, Y | 1 |
Admon, R | 1 |
Mellem, MS | 1 |
Belleau, EL | 1 |
Kaiser, RH | 1 |
Clegg, R | 1 |
Beltzer, M | 1 |
Goer, F | 1 |
Vitaliano, G | 1 |
Ahammad, P | 1 |
Pizzagalli, DA | 1 |
Mohamed, AM | 1 |
Habib, MZ | 1 |
Ebeid, MA | 1 |
Abdelraouf, SM | 1 |
El Faramawy, Y | 1 |
Aboul-Fotouh, S | 1 |
Magdy, Y | 1 |
Wang, G | 1 |
Zhou, B | 1 |
Zheng, L | 1 |
Ni, Y | 1 |
Pan, A | 1 |
Smith, RC | 1 |
Leucht, S | 1 |
Davis, JM | 1 |
Pasquini, M | 1 |
Berardelli, I | 1 |
Calabrò, F | 1 |
Roselli, V | 1 |
Hefner, S | 1 |
Biondi, M | 1 |
Rico-Villademoros, F | 1 |
Calandre, EP | 1 |
Slim, M | 1 |
Peuskens, J | 1 |
Möller, HJ | 1 |
Puech, A | 1 |
Kopecek, M | 1 |
Bares, M | 1 |
Svarc, J | 1 |
Dockery, C | 1 |
Horácek, J | 1 |
Lecrubier, Y | 3 |
Quintin, P | 1 |
Bouhassira, M | 1 |
Perrin, E | 1 |
Lancrenon, S | 1 |
Carvalho, AF | 1 |
Nunes-Neto, PR | 1 |
Cavalcante, JL | 1 |
Oliveira Lima, MC | 1 |
Torta, R | 1 |
Berra, C | 1 |
Binaschi, L | 1 |
Borio, R | 1 |
Peritogiannis, V | 1 |
Goulia, P | 1 |
Pappas, D | 1 |
Hyphantis, T | 1 |
Mavreas, V | 1 |
Politis, AM | 1 |
Papadimitriou, GN | 1 |
Theleritis, CG | 1 |
Psarros, C | 1 |
Soldatos, CR | 1 |
Boyer, P | 2 |
Puech, AJ | 1 |
Dewailly, J | 1 |
Aubin, F | 1 |
Perrault, G | 1 |
Schoemaker, H | 1 |
Scatton, B | 1 |
Turjanski, S | 2 |
Rein, W | 2 |
Papp, M | 1 |
Wieronska, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of Dopamine on Reward Processing[NCT01253421] | Phase 1 | 159 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
Early Life Stress and Depression: Molecular and Functional Imaging Approaches[NCT01701258] | Phase 1 | 153 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.2231 |
MDD-placebo | -0.0391 |
HC-amisulpride | -0.0938 |
HC-placebo | 0.0582 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after Reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.5783 |
MDD-placebo | -0.2673 |
HC-amisulpride | -0.33 |
HC-placebo | 0.1955 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between caudate and dorsal anterior cingulate cortex (dACC) in response to reward outcomes (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.3628 |
MDD-placebo | 0.3881 |
HC-amisulpride | 0.2992 |
HC-placebo | 0.6192 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.2446 |
MDD-placebo | 0.0736 |
HC-amisulpride | 0.1356 |
HC-placebo | 0.2182 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.9377 |
MDD-placebo | 0.1578 |
HC-amisulpride | 0.4018 |
HC-placebo | 0.954 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between nucleus accumbens (NAcc) and mid-cingulate cortex (MCC) in response to reward outcomes. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.4375 |
MDD-placebo | 0.324 |
HC-amisulpride | 0.4846 |
HC-placebo | 0.4877 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from penalties during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from penalty trials. (NCT01253421)
Timeframe: administered after scan
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.2428 |
MDD-placebo | 0.29 |
HC-amisulpride | 0.2207 |
HC-placebo | 0.2391 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from rewards during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from reward trials. (NCT01253421)
Timeframe: administered after scan
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.6271 |
MDD-placebo | 0.7575 |
HC-amisulpride | 0.823 |
HC-placebo | 0.7545 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation (beta) after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.6338 |
MDD-placebo | 0.1709 |
HC-amisulpride | -0.14 |
HC-placebo | 0.436 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.4969 |
MDD-placebo | 0.3955 |
HC-amisulpride | 0.4169 |
HC-placebo | 0.3808 |
"This is a measure of area under the curve in relation to ground, a measure of total cortisol output, in response to acute stress. The acute stressor was the Maastricht Acute Stress Test (MAST). The area under the curve includes all 5 cortisol measures, with one measure before the stressor and the other four measures collected after the stressor. Given that the cortisol data were positively skewed, the cortisol measures were normalized via a log transformation prior to calculating the area under the curve.~Area under the curve with respect to ground (AUCG) is calculated AUC_g=(((cort2_log + cort1_log) * cort_t1_time) / 2)+(((cort3_log+cort2_log)*cort_t2_time)/2)+(((cort4_log+cort3_log)*cort_t3_time)/2)+(((cort5_log+cort4_log)*cort_t4_time)/2). Cort_logs are the log transformed cortisol output data (ng/ml) and the cort_times are the time spans in between each cortisol assessment." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | [log (ng/ml)]*min (Mean) |
---|---|
Control Group | 156.58 |
MDD Group | 186.78 |
CSA/RES Group | 152.13 |
CSA/MDD Group | 179.16 |
This statistic shows the impact of the stress manipulation on the participant's salivary cortisol output. Saliva samples were collected at 5 distinct time points throughout the study session. The first saliva sample (Cort 1) was collected when the participant began the eeg session. The second (Cort 2)was taken at the end of the acute stressor. The third (Cort 3) was taken approximately fifteen minutes after the second. The fourth (Cort 4) was taken approximately ten minutes after the third. The fifth (Cort 5) was taken approximately 40 minutes after the fourth. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | ng/ml (Mean) | ||||
---|---|---|---|---|---|
Cort1 | Cort2 | Cort3 | Cort4 | Cort5 | |
Control Group | 9.80 | 9.11 | 15.55 | 12.89 | 7.07 |
CSA/MDD Group | 14.19 | 8.63 | 14.31 | 14.22 | 11.01 |
CSA/RES Group | 10.15 | 9.51 | 10.75 | 8.99 | 7.41 |
MDD Group | 12.53 | 12.28 | 15.23 | 16.30 | 10.34 |
"Utilizing 11C-altropane during positron emission tomography (PET) scanning allows us to measure dopamine active transporter (DAT) binding potential.~Our outcome measure is Nondisplacable Binding Potential (BPND). BPND refers to the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue.~*Higher BPND scores indicate greater binding potential" (NCT01701258)
Timeframe: 1 hour PET scan (Session 3)
Intervention | Ratio (Mean) | ||
---|---|---|---|
Caudate | Putamen | Accumbens | |
Control Group | 3.191 | 3.361 | 2.159 |
CSA/MDD Group | 3.216 | 3.318 | 2.149 |
CSA/RES Group | 3.175 | 3.241 | 2.103 |
MDD Group | 3.161 | 3.359 | 2.103 |
"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward cues during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Drug & fMRI Session (Session 2)
Intervention | beta weight (slope) (Mean) | |||||
---|---|---|---|---|---|---|
Caudate Response to Reward Cues | Caudate Response to Neutral Cues | Putamen Response to Reward Cues | Putamen Response to Neutral Cues | Accumbens Response to Reward Cues | Accumbens Response to Neutral Cues | |
Control-amisulpride | .200 | .222 | .608 | .455 | .401 | .016 |
Control-placebo | .468 | .185 | .663 | .518 | .480 | .120 |
CSA/MDD-amisulpride | .514 | .254 | .550 | .550 | .692 | .385 |
CSA/MDD-placebo | .054 | -.243 | .468 | .357 | .255 | .040 |
CSA/RES-amisulpride | .511 | .050 | .745 | .493 | .679 | -.123 |
CSA/RES-placebo | .079 | -.370 | .419 | .240 | .310 | -.381 |
MDD-amisulpride | .403 | .047 | .698 | .384 | .351 | -.111 |
MDD-placebo | .608 | .156 | .814 | .621 | .428 | .140 |
"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward feedback during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Session 2 (fMRI session)
Intervention | beta weight (slope) (Mean) | |||||
---|---|---|---|---|---|---|
Caudate Response to Reward Feedback | Caudate Response to Neutral Feedback | Putamen Response to Reward Feedback | Putamen Response to Neutral Feedback | Accumbens Response to Reward Feedback | Accumbens Response to Neutral Feedback | |
Control-amisulpride | -.613 | -.793 | -.533 | -.375 | .074 | -.503 |
Control-placebo | -.273 | -.105 | -.131 | .164 | .069 | .109 |
CSA/MDD-amisulpride | -.101 | -.233 | -.018 | -.021 | -.158 | .010 |
CSA/MDD-placebo | .040 | -.608 | .063 | -.418 | .839 | -.332 |
CSA/RES-amisulpride | -.197 | -.501 | -.087 | -.142 | -.046 | -.079 |
CSA/RES-placebo | -.905 | -.959 | -.304 | -.276 | -.713 | -.819 |
MDD-amisulpride | -.819 | -.865 | -.031 | -.229 | -.554 | -.456 |
MDD-placebo | -.773 | -.733 | -.357 | -.108 | -.215 | -.039 |
"EEG was recorded during the probabilistic reward task (the PRT task). Participants completed the Probabilistic Reward Task (PRT) twice throughout the experiment, once before stress and once after stress. The stressor was the Maastricht Acute Stress Test (MAST). This statistic shows the effect that childhood sexual abuse (CSA) and diagnosis had on a reward-related positivity EEG component recorded during the PRT, before and after stress.~Higher reward positivity amplitudes indicate a stronger neural response to reward and lower amplitudes indicate a lower neural response to rewards." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | amplitude (microvolts) (Mean) | |
---|---|---|
Pre MAST | Post MAST | |
Control Group | 2.71 | 2.06 |
CSA/MDD Group | 4.15 | 3.90 |
CSA/RES Group | 2.16 | 2.30 |
MDD Group | 4.75 | 4.99 |
The participant's performance on the Probabilistic Reward Task (PRT) was assessed both before and after an acute stressor. The PRT is a behavioral task that measures an individual's ability to learn from rewarding stimuli and incorporate this learning into their response style (response bias). The acute stressor was the Maastricht Acute Stress Test (MAST). The score obtained is a ratio of the number of times participants correctly choose the high reward stimuli versus the low rewarding stimuli. Response bias scores range between -1 and +1. Higher response bias scores indicate a stronger response bias toward high reward stimuli. A negative response bias indicates a stronger bias toward low reward stimuli. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | Ratio (Response Bias Score) (Mean) | |||
---|---|---|---|---|
PRT Block1: Before MAST | PRT Block2: Before MAST | PRT Block1: After MAST | PRT Block2: After MAST | |
Control Group | 0.028 | 0.124 | 0.128 | 0.245 |
CSA/MDD Group | 0.167 | 0.168 | 0.048 | 0.127 |
CSA/RES Group | 0.092 | 0.130 | 0.079 | 0.143 |
MDD Group | 0.117 | 0.155 | 0.078 | 0.128 |
5 reviews available for dan 2163 and Depression
Article | Year |
---|---|
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Clozapine; Depression; Humans; Imidazoles; | 2019 |
Is amisulpride safe when prescribed to breast and prostate cancer patients?
Topics: Amisulpride; Antidepressive Agents; Breast Neoplasms; Depression; Female; Humans; Hyperprolactinemia | 2013 |
Current status of atypical antipsychotics for the treatment of fibromyalgia.
Topics: Amisulpride; Antipsychotic Agents; Anxiety; Benzodiazepines; Comorbidity; Depression; Dibenzothiazep | 2014 |
[The place of amisulpride in the atypical neuroleptic class].
Topics: Amisulpride; Animals; Depression; Humans; Limbic System; Neurologic Examination; Rats; Receptors, Do | 1996 |
Clinical update on amisulpride in deficit schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind | 1997 |
8 trials available for dan 2163 and Depression
Article | Year |
---|---|
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
Topics: Amisulpride; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders; Do | 2022 |
Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets.
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chlo | 2022 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Hyperprolactinemia after low dose of amisulpride.
Topics: Adult; Amisulpride; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Depression; Dr | 2004 |
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines | 2006 |
Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.
Topics: Aged; Aged, 80 and over; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Depression; Drug | 2008 |
Treatment of negative symptoms in schizophrenia with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind | 1995 |
Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group.
Topics: Adult; Aged; Amisulpride; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Depre | 1997 |
7 other studies available for dan 2163 and Depression
Article | Year |
---|---|
Amisulpride alleviates chronic mild stress-induced cognitive deficits: Role of prefrontal cortex microglia and Wnt/β-catenin pathway.
Topics: Amisulpride; Animals; Attention; Behavior, Animal; beta Catenin; Cognition Disorders; Depression; En | 2020 |
Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.
Topics: Amisulpride; Antipsychotic Agents; Case-Control Studies; Depression; Humans; Psychiatric Status Rati | 2020 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M | 2002 |
Amisulpride augmentation after the failure of citalopram for depression: a case report.
Topics: Adult; Amisulpride; Citalopram; Depression; Dopamine Antagonists; Drug Therapy, Combination; Female; | 2007 |
Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies.
Topics: Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Cohort Studies; Depression; Femal | 2007 |
Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease.
Topics: Adult; Amenorrhea; Amisulpride; Antipsychotic Agents; Depression; Drug Interactions; Female; Humans; | 2007 |
Antidepressant-like activity of amisulpride in two animal models of depression.
Topics: Amisulpride; Animals; Antidepressive Agents; Antipsychotic Agents; Depression; Disease Models, Anima | 2000 |